The third generation of gene sequencer was born

According to Xinhua News Agency, Shenzhen, August 1st (Reporter Zhou Ke) The third-generation gene sequencer independently developed by the Southern University of Science and Technology He Jiankui team was born in Shenzhen. At present, small batch prototype production has been completed. After mass production, everyone is expected to have an individual Exclusive “gene ID card”.

The gene sequencer has been reviewed by the international scientific community and filed with the Shenzhen Food and Drug Administration for high-throughput sequencing and obtaining sample sequence information. The core member of the team, He Jiankui, is an associate professor of the post-80s Department of Biology. He said that the third-generation gene sequencer has made key breakthroughs in the fields of optics and biological preparations. It can directly read the most primitive DNA or RNA molecular sequences, which can not only increase the speed of gene sequencing, but also reduce the cost of clinical gene sequencing. “It is estimated that around 2019, people can test their genetic information and create their own ‘gene ID cards’ for only about $100.”

Yu Jun, former deputy director of the Beijing Institute of Genomics, Chinese Academy of Sciences, said that the third-generation gene sequencer developed by He Jiankui’s team has technical advantages such as single-molecule resolution, no GC preference, and simple and fast sample processing. This device not only overcomes the relatively low-throughput shortcomings of single-molecule sequencing, but also provides the possibility of direct RNA sequencing. Its application will cover both scientific research and clinical fields.

U.S. court labelled genetically modified partners as carcinogenic

OFweek Medical Network News GMOs are unfavorable, this time some people have to sleep and eat even more. According to reports, California judge Kristi Kapetan issued a formal ruling that the genetically modified partner glyphosate (Roundup, Chinese name: Roundup) sold in California must be labeled as carcinogenic! The judge will issue a formal decision soon. Samdelson, a spokesperson for the California Office of Environmental Health Hazard Assessment (OEHHA), told the Associated Press that the regulator is waiting for the judge’s formal decision before advancing the warning label. As soon as the news came out, major media in the United States, Reuters, Bloomberg and other world media reported that the use of corruption to conceal the truth about the harm of genetically modified organisms has become clear.

Not only that, but even more shocking is that California’s Bill 65 identified an important basis: California farmer Jack Kaul who died of cancer. Jack Kaul has been using glyphosate on his 20-acre fruit and vegetable farm for nearly 30 years and found that he had cancer. In this regard, Kaul’s wife and dozens of farmers jointly sued Monsanto. The grounds for their lawsuit were: Jack Kaul did not obtain relevant cancer risk warnings due to long-term exposure to glyphosate, which resulted in abnormal death from cancer. Monsanto deliberately played down the risk of genetically modified partner glyphosate.

Not only that, the plaintiff’s attorney once asked the judge to summon Jess Rowland, a senior U.S. Environmental Protection Agency official who had resigned in 2016, in order to clarify his abnormal relationship with Monsanto. This request was opposed by Monsanto and the US Environmental Protection Agency. Monsanto even asked the court to prohibit the plaintiff from disclosing hard-earned information.

Recently, the plaintiff’s attorney obtained evidence such as emails from the late toxicology expert Marion Copley of the U.S. Environmental Protection Agency (EPA). During his tenure at the Environmental Protection Agency, Copley wrote reports that basically confirmed that glyphosate would cause cancer based on the results of animal experiments. Senior official of the Environmental Protection Agency Jess Rowland once intimidated the staff, including Copley, to change the content of this report to meet the commercial interests of chemical giants such as Monsanto.

In other words, the California judge told people: “There is no problem with genetically modified and partner glyphosate.” It was based on the fact that Monsanto wooed and corrupted US Environmental Protection Agency officials to conceal the facts of the harm, and based on lies. “GMO hides the greatest transnational corruption”, this cruel reality once again revealed the tip of the iceberg.

It seems that the actions of the California judges have made it difficult to conceal genetically modified corruption in the United States.

The last thing to note is that California’s Act 65 has factual basis and the conclusion of the International Agency for Research on Cancer (IARC) that the genetically modified partner glyphosate is “definitely carcinogenic” to mice and that it is “probably carcinogenic” to humans. Moreover, the United States is a case law country. According to the case law system, the legal rules in a certain judgment not only apply to the case, but also often serve as a precedent and apply to cases under the jurisdiction of the court or lower courts in the future. As long as the basic facts of the case are the same or similar, they must be handled in accordance with the rules set by the precedent. This is the so-called “stare decisis” principle. The day when California Act No. 65 was officially promulgated was when many courts in the United States sentenced the genetically modified partner glyphosate to “death penalty” based on the Act. In the future, no matter who, as long as they say that there is no problem with genetic modification, people will think that this is not only unethical and untrustworthy, but also shameless and rascal.

Gene medicine will be supported by a series of national policies

Our country will further promote the construction of genetic technology infrastructure, and promote the application of related technologies in the medical field with a number of measures.

Gene sequencing concept stocks rose

It is understood that within this year, my country will officially start the construction of the second phase of the national gene bank, and it is expected that the total amount of gene data will exceed the sum of the three major gene banks in the United States, Europe and Japan within five years. At the same time, my country will accelerate the establishment of a genetic technology system and infrastructure from genetic testing to individualized precision immunization. In addition, my country will issue relevant policies to prioritize the review of genetic testing products identified as innovative medical (, buy-in) devices in accordance with the approval procedures for innovative medical devices, speed up the entry of innovative medical service projects into the medical system, and promote the entry of new technologies into clinical use .

Research reports of securities firms such as CICC Securities and Zhongtai Securities believe that my country has a huge demand for disease screening, cancer treatment, and chronic disease treatment. With the entry of genetic medicine into clinical applications, the above three fields and related markets will be the first to enter a period of rapid growth. The total market size is expected to reach 300 billion yuan by 2020.

List of gene sequencing concept stocks:

Zixin Pharmaceutical (,Buy): The company cooperates with Beijing Institute of Genomics, Chinese Academy of Sciences to develop a second-generation gene sequencer

Qianyao Machine (,Buy): Participate in Honghao Gene to enter the gene sequencing market, and has successfully developed 5 types of personalized drug therapy gene detection chips for hypertension and other types

Daan Gene (,Buy): Daan Gene is the second company approved for NIPT-related genetic testing products, and has 8 clinical testing centers across the country.

Anke Biology (,Buy): The subsidiary Sino-German Meilian operates businesses involving biological gene sequencing and DNA testing.
Zhongyuan Concord (,Buy): Construction and operation of Zhongyuan Concord (Tianjin) Medical Laboratory, specializing in research and application of genetic testing related technologies, and entering the field of gene sequencing